版本:
中国

BRIEF-Glycomimetics doses first patient in Phase 1 clinical trial of drug candidate GMI-1271 for multiple myeloma

Sept 14 Glycomimetics Inc

* Glycomimetics Doses First Patient In Phase 1 Clinical Trial Of Drug Candidate GMI-1271 for multiple myeloma

* Company anticipates enrolling 24 participants in trial

* Newly initiated multi-center, open-label dose escalation trial, has begun in ireland, measures efficacy, safety and pharmacokinetics Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐